Acorda Therapeutics Operating Margin 2006-2021 | ACOR

Current and historical operating margin for Acorda Therapeutics (ACOR) over the last 10 years. The current operating profit margin for Acorda Therapeutics as of September 30, 2021 is -0.26%.
Acorda Therapeutics Operating Margin Historical Data
Date TTM Revenue TTM Operating Income Operating Margin
2021-09-30 $0.13B $-0.15B -112.31%
2021-06-30 $0.15B $-0.11B -70.39%
2021-03-31 $0.15B $-0.10B -65.58%
2020-12-31 $0.15B $-0.08B -50.98%
2020-09-30 $0.17B $0.01B 8.48%
2020-06-30 $0.16B $-0.26B -163.13%
2020-03-31 $0.18B $-0.27B -155.68%
2019-12-31 $0.19B $-0.31B -161.98%
2019-09-30 $0.21B $-0.37B -177.25%
2019-06-30 $0.31B $-0.09B -28.43%
2019-03-31 $0.41B $-0.01B -1.22%
2018-12-31 $0.47B $0.04B 8.07%
2018-09-30 $0.59B $-0.13B -22.20%
2018-06-30 $0.59B $-0.16B -27.38%
2018-03-31 $0.57B $-0.22B -37.80%
2017-12-31 $0.59B $-0.23B -39.52%
2017-09-30 $0.54B $-0.01B -2.41%
2017-06-30 $0.54B $-0.02B -2.99%
2017-03-31 $0.52B $-0.03B -6.31%
2016-12-31 $0.52B $-0.04B -6.73%
2016-09-30 $0.51B $-0.03B -6.27%
2016-06-30 $0.52B $-0.00B -0.19%
2016-03-31 $0.51B $0.02B 3.73%
2015-12-31 $0.49B $0.04B 7.10%
2015-09-30 $0.48B $0.03B 6.67%
2015-06-30 $0.44B $0.03B 6.16%
2015-03-31 $0.42B $0.03B 7.60%
2014-12-31 $0.40B $0.04B 8.96%
2014-09-30 $0.38B $0.05B 12.73%
2014-06-30 $0.36B $0.04B 10.67%
2014-03-31 $0.35B $0.04B 10.40%
2013-12-31 $0.34B $0.03B 9.20%
2013-09-30 $0.33B $0.02B 5.85%
2013-06-30 $0.32B $0.02B 5.68%
2013-03-31 $0.31B $0.01B 4.58%
2012-12-31 $0.31B $0.03B 8.20%
2012-09-30 $0.30B $0.04B 12.46%
2012-06-30 $0.31B $0.05B 15.34%
2012-03-31 $0.30B $0.04B 14.57%
2011-12-31 $0.29B $0.04B 11.99%
2011-09-30 $0.29B $0.03B 9.09%
2011-06-30 $0.26B $0.02B 7.00%
2011-03-31 $0.24B $0.01B 4.68%
2010-12-31 $0.19B $-0.01B -4.69%
2010-09-30 $0.14B $-0.04B -25.18%
2010-06-30 $0.09B $-0.07B -74.44%
2010-03-31 $0.06B $-0.08B -138.33%
2009-12-31 $0.05B $-0.08B -150.00%
2009-09-30 $0.05B $-0.08B -153.85%
2009-06-30 $0.05B $-0.08B -163.27%
2009-03-31 $0.05B $-0.08B -159.57%
2008-12-31 $0.05B $-0.07B -155.32%
2008-09-30 $0.05B $-0.07B -145.65%
2008-06-30 $0.04B $-0.06B -129.55%
2008-03-31 $0.04B $-0.05B -114.29%
2007-12-31 $0.04B $-0.04B -105.26%
2007-09-30 $0.04B $-0.03B -91.43%
2007-06-30 $0.03B $-0.03B -96.77%
2007-03-31 $0.03B $-0.03B -78.13%
2006-12-31 $0.03B $-0.02B -85.71%
2006-09-30 $0.02B $-0.03B -113.04%
2006-06-30 $0.02B $-0.03B -130.00%
2006-03-31 $0.01B $-0.03B -340.00%
2005-12-31 $0.01B $-0.03B -566.67%
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.032B $0.153B
Acorda Therapeutics, Inc. is a biotechnology company developing and commercializing neurology therapies for Parkinson's disease, migraine and multiple sclerosis. Acorda has a pipeline of novel neurological therapies addressing a range of disorders, including Parkinson's disease and multiple sclerosis. Acorda markets three FDA-approved therapies, including AMPYRA? (dalfampridine) Extended Release Tablets, 10 mg.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $125.477B 7.93
Bio-Rad Laboratories (BIO.B) United States $23.034B 46.74
QIAGEN (QGEN) Netherlands $12.874B 21.80
Biohaven Pharmaceutical Holding (BHVN) United States $7.457B 0.00
Arcus Biosciences (RCUS) United States $3.257B 0.00
Emergent Biosolutions (EBS) United States $2.378B 8.55
Myovant Sciences (MYOV) United Kingdom $1.780B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.529B 0.00
Zymeworks (ZYME) Canada $0.908B 0.00
Ambrx Biopharma (AMAM) United States $0.407B 0.00
SQZ Biotechnologies (SQZ) United States $0.345B 0.00
Enzo Biochem (ENZ) United States $0.164B 16.09